Long-Term Effects of Botulinum Type A Neurotoxin on the Release of Noradrenaline from PC12 Cells

  • Clifford C. Shone

Abstract

Clostridium botulinum type A neurotoxin (BoNTA) slowly inhibits the calcium-dependent release of noradrenaline from PC12 cells in a dose-dependent manner. The effects of BoNTA on PC12 cells are shown to persist for several days and in subsequent cell generations. Examination of the molecular form of cell-associated 125I-labelled BoNTA after 96h incubation within PC12 cells showed virtually no detectable degradation of either the heavy or light chains of the neurotoxin. The data suggest that BoNTA is relatively stable within the PC12 cell with a half-life in the order of several days. More than 50% of the membrane-associated BoNTA within the cell exists in the form of high molecular weight, disulphide-linked aggregates and these appear to be enriched in the light chain of the neurotoxin. A possible role in action of BoNTA for these aggregates is discussed.

Keywords

PC12 Cell Light Chain Supernatant Fluid Noradrenaline Release Botulinum Neurotoxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Black, J.D. and Dolly, J.O., 1986, Interaction of 125I-labelled botulinum neurotoxin with nerve terminals J. Cell Biol., 103: 535–544.PubMedCrossRefGoogle Scholar
  2. De Paiva, A. and Dolly, J.O., 1990, Light chain of neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes, FEBS Lett., 277: 171–174.PubMedCrossRefGoogle Scholar
  3. Diliberto, Jr., E.J., Viveros, O.H. and Axelrod, J., 1976, Subcellular localisation of protein carboxymethylase and its endogenous substrates in the adrenal medulla: possible role in excitation-secretion coupling, Proc. Natl. Acad. Sci. USA, 73: 4050–4054.PubMedCrossRefGoogle Scholar
  4. Dolly, J.O., Black, J.D., Williams, R.S., and Melling, J., 1984, Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalisation, Nature, 307: 457–460.PubMedCrossRefGoogle Scholar
  5. Enoch, H.G, and Strittmatter, P., 1979, Formation and properties of 1000A diameter, single bilayer phospholipid vesicles, Proc. Natl. Acad. Sci. USA, 76: 145–149.PubMedCrossRefGoogle Scholar
  6. Greene, L.A. and Rein, G., 1977, Synthesis, storage and release of acetylcholine by a noradrenergic, pheochromocytoma cell line, Nature, 268: 349–351.PubMedCrossRefGoogle Scholar
  7. Greene, L.A. and Tischler, A.S., 1976, Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor, Proc. Natl. Acad. Sci. USA, 73: 2424–2428.PubMedCrossRefGoogle Scholar
  8. Laemmli, U.K., 1970, Cleavage of the structural protein during the assembly of the head of the bacteriophage T4, Nature, 227: 680–685.PubMedCrossRefGoogle Scholar
  9. Mclness, C. and Dolly, J.O., 1990, Calcium-dependent noradrenaline release from permeabilised PC12 cells is blocked by botulinum neurotoxin A or its light chain, FEBS Lett. 261: 323–326.CrossRefGoogle Scholar
  10. Schubert, D. and Klier, F.G., 1977, Storage and release of acetylcholine by a clonal cell line, Proc. Natl. Acad. Sci. USA, 74: 5184–5188.PubMedCrossRefGoogle Scholar
  11. Shone, C.C., 1987, Clostridium botulinum neurotoxins: their and modes of action, in:“Natural Toxicants in Foods”, D. Watson ed., pp 11–51, Ellis Horwood Ltd., Chichester, U.K.Google Scholar
  12. Shone, C.C., Hambleton, P. and Melling, J., 1985, Inactivation of Clostridium botulinum type A neurotoxin and purification of two tryptic fragments, Eur. J. Biochem. 151: 75–82.PubMedCrossRefGoogle Scholar
  13. Simpson, L.L., 1981, The origin, structure and pharmacological action of botulinum toxin, Pharmacol. Rev. 33: 155–188.PubMedGoogle Scholar
  14. Stecher, B., Gratzl, M. and Ahnert-Hilger, G., 1989a, Reductive chain separation of botulinum A toxin — a prerequisite to its inhibitory action on exocytosis in chromaffin cells. FEBS Lett., 248: 23–27.PubMedCrossRefGoogle Scholar
  15. Stecher, B., Weller, U., Habermann, E., Gratzl and Ahnert-Hilger, G., 1989b, The light chain but not the heavy chain of botulinum A toxin inhibits exocytosis from permeabilized adrenal chromaffin cells, FEBS Lett. 255: 391–394.PubMedCrossRefGoogle Scholar
  16. Wadsworth, J.D.F., Desai, M., King, H.K., Tranter, H.S., Hambleton, P., Melling, J., Dolly, J.O. and Shone, C.C., 1990, Botulinum type F neurotoxin: purification, radiolabelling and binding to rat brain synaptosomes, Biochem. J. 268: 123–128.PubMedGoogle Scholar
  17. Williams, R.S., Tse, C.-K., Dolly, J.O., Hambleton, P. and Melling, J., 1983, Radiolabelling of botulinum type A neurotoxin with retention of biological activity and its binding to rat brain synaptosomes, Eur. J. Biochem. 131: 437–445.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Clifford C. Shone
    • 1
  1. 1.Division of BiologicsCentre for Applied Microbiology and ResearchSalisbury WiltsUK

Personalised recommendations